Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amit Aggarwal

Showing results (121-130 of 135) with videos related to

Pageof 14
Sort By:
Communications Biology|July 11, 2020
Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinomaAnne-Lise Peille, Vincent Vuaroqueaux, Swee-Seong Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2019
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>-</sup> Breast CancerSara A Hurvitz, Miguel Martin, Michael F Press, et al.
Scientific Reports|July 3, 2020
Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasisJiangang Liu, Yong Beom Cho, Hye Kyung Hong, et al.
Scientific Reports|October 27, 2019
Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patientsSteven M Bray, Jeeyun Lee, Seung Tae Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2023
Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform NeurofibromaAlyssa C Flint, Dana K Mitchell, Steven P Angus, et al.
Nature Communications|November 20, 2014
Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencingSwee Seong Wong, Kyoung-Mee Kim, Jason C Ting, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2024
Correction: Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform NeurofibromaAlyssa C Flint, Dana K Mitchell, Steven P Angus, et al.
Nature Communications|April 7, 2022
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trialMichiel S van der Heijden, Thomas Powles, Daniel Petrylak, et al.
The Lancet. Oncology|September 30, 2021
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 studyJuan W Valle, Arndt Vogel, Crystal S Denlinger, et al.
Molecular Cancer Therapeutics|April 2, 2014
A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor modelsTinggui Yin, Maria J Lallena, Emiko L Kreklau, et al.
Pageof 14

Showing results (121-130 of 135) with videos related to

Sort By:
Pageof 14
Communications Biology|July 11, 2020
Evaluation of molecular subtypes and clonal selection during establishment of patient-derived tumor xenografts from gastric adenocarcinomaAnne-Lise Peille, Vincent Vuaroqueaux, Swee-Seong Wong, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 17, 2019
Potent Cell-Cycle Inhibition and Upregulation of Immune Response with Abemaciclib and Anastrozole in neoMONARCH, Phase II Neoadjuvant Study in HR<sup>+</sup>/HER2<sup>-</sup> Breast CancerSara A Hurvitz, Miguel Martin, Michael F Press, et al.
Scientific Reports|July 3, 2020
Molecular dissection of CRC primary tumors and their matched liver metastases reveals critical role of immune microenvironment, EMT and angiogenesis in cancer metastasisJiangang Liu, Yong Beom Cho, Hye Kyung Hong, et al.
Scientific Reports|October 27, 2019
Genomic characterization of intrinsic and acquired resistance to cetuximab in colorectal cancer patientsSteven M Bray, Jeeyun Lee, Seung Tae Kim, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 5, 2023
Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform NeurofibromaAlyssa C Flint, Dana K Mitchell, Steven P Angus, et al.
Nature Communications|November 20, 2014
Genomic landscape and genetic heterogeneity in gastric adenocarcinoma revealed by whole-genome sequencingSwee Seong Wong, Kyoung-Mee Kim, Jason C Ting, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 1, 2024
Correction: Combined CDK4/6 and ERK1/2 Inhibition Enhances Antitumor Activity in NF1-Associated Plexiform NeurofibromaAlyssa C Flint, Dana K Mitchell, Steven P Angus, et al.
Nature Communications|April 7, 2022
Predictive biomarkers for survival benefit with ramucirumab in urothelial cancer in the RANGE trialMichiel S van der Heijden, Thomas Powles, Daniel Petrylak, et al.
The Lancet. Oncology|September 30, 2021
Addition of ramucirumab or merestinib to standard first-line chemotherapy for locally advanced or metastatic biliary tract cancer: a randomised, double-blind, multicentre, phase 2 studyJuan W Valle, Arndt Vogel, Crystal S Denlinger, et al.
Molecular Cancer Therapeutics|April 2, 2014
A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor modelsTinggui Yin, Maria J Lallena, Emiko L Kreklau, et al.
Pageof 14